Compare Meta Platforms Inc (META) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs Zoetis Inc — how do they compare? Meta Platforms Inc trades at $647.01 (market cap $1.64T), while Zoetis Inc trades at $75.56 (market cap $31.95B). The key difference: Meta Platforms Inc is far larger — about 51.3× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.78%). Which is the better fit depends on your goals.
| META | ZTS | |
|---|---|---|
Market Cap | $1.64T | $31.95B |
Volume | 24,093,972 | — |
Sector | Media | Health |
52-Week High | $790.00 | $156.76 |
52-Week Low | $525.72 | $71.91 |
Enterprise Value | $1.65T | $39.24B |
Dividend Yield | 0.33% | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Meta Platforms (META) trades at $646.96, up 0.15% with a bullish technical signal supported by moving averages. The company demonstrates strong fundamentals with $201B revenue in 2025, 32.84% net margin, and consistent earnings beats. Recent AI developments including Muse Spark launch and a $21B CoreWeave deal highlight growth initiatives. Technical indicators show support at $631 and resistance at $657, with RSI in neutral territory suggesting balanced momentum.
Outlook remains positive with 79% analyst buy ratings and $817 consensus target offering 26% upside. Key opportunities include AI monetization and revenue growth to $215B in 2026. Risks involve ongoing youth addiction lawsuits, regulatory scrutiny, and high capital expenditures. Institutional ownership trends show continued confidence with recent stake increases by American National Bank.
Zoetis (ZTS) trades at $76.05, down 0.67% on the day, with a neutral technical signal and bearish moving averages. The company maintains strong fundamentals with a 28.03% net income margin and 67.75% ROE, though Q1 2026 earnings missed expectations. Recent news highlights multiple securities class action lawsuits filed against the company, creating near-term uncertainty despite the launch of new product Lenivia in Canada and EU markets.
The stock presents a mixed outlook with attractive valuation metrics (P/E 12.55) and analyst consensus price target of $101.43 suggesting 33% upside potential. However, legal challenges and the recent earnings miss pose significant near-term risks. Institutional sentiment remains divided with 47% buy ratings versus 53% hold ratings, indicating cautious optimism amid legal headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
